
MAXIMUS, Inc.
MMSMAXIMUS, Inc. (MMS) is a consulting and services company that specializes in implementing government programs related to health, wellness, and social services. Founded in 1975, it primarily provides operational, technology, and consulting services to federal, state, and local governments to improve their delivery of public programs such as healthcare, Medicaid, and social security.
Dividend History
Investors can expect a dividend payout of $0.33 per share, scheduled to be distributed in 44 days on August 31, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 31, 2026 | $0.33 | 2026-08-14 | 2026-08-14 |
| June 1, 2026 | $0.33 | 2026-05-15 | 2026-05-15 |
| March 2, 2026 | $0.33 | 2026-02-13 | 2026-02-13 |
| December 1, 2025 | $0.30 | 2025-11-14 | 2025-11-14 |
| August 31, 2025 | $0.30 | 2025-08-15 | 2025-08-15 |
Dividends Summary
- Consistent Payer: MAXIMUS, Inc. has rewarded shareholders with 87 dividend payments over the past 21 years.
- Total Returned Value: Investors who held MMS shares during this period received a total of $13.69 per share in dividend income.
- Latest Payout: The most recent dividend of $0.33/share was paid 47 days ago, on June 1, 2026.
- Yield & Schedule: MMS currently pays dividends quarterly with an annual yield of 2.21%.
- Dividend Growth: Since 2005, the dividend payout has grown by 230.0%, from $0.10 to $0.33.
- Dividend Reliability: MMS has maintained or increased its dividend for 53 consecutive payments.
Company News
Maximus, a performance medicine telehealth company, has been ranked #7 on the Financial Times' list of The Americas' Fastest Growing Companies 2026, based on compound annual revenue growth between 2021-2024. The company, founded in 2020, offers online treatments including testosterone optimization, GLP-1 weight loss, and peptide therapies, and is...
Maximus has developed a groundbreaking topical oxytocin cream that provides sustained hormone release for up to 12-16 hours through a novel transdermal delivery technology, addressing previous challenges in maintaining therapeutic oxytocin levels.
The Case Management Market is projected to grow from $7.89 billion in 2023 to $17.43 billion by 2032, driven by the rising need for efficient workflow automation and regulatory compliance across industries.
Investors target stocks that have been on a bullish run lately. Stocks like AMKR, THC, LDOS and MMS that are seeing price strength have a high chance of carrying the momentum forward.
Commitment to shareholder returns makes Maximus (MMS) a reliable way for investors to compound wealth over the long term.



